, Volume 16, Issue 6, pp 623–629 | Cite as

Mucosal protective activity of prostaglandin analogs in rodent colonic inflammation

  • D. J. Fretland
  • D. L. Widomski
  • C. P. Anglin
  • R. E. Walsh
  • S. Levin
  • A. F. Gasiecki
  • P. W. Collins
Original Articles


The mucosal protective prostaglandin analogs misoprostol, enisoprost, and SC-46275 (the 17E-18-cyclopentenyl analog of enisoprost) were tested in mouse and rat colitis induced by the intrarectal instillation of dilute acetic acid. Colitis was assessed by histology and colonic levels of myeloperoxidase (a neutrophil marker enzyme). When given as enemas 30 min ahead of colitis induction, 15(R)-15-methyl-PGE2 (arbaprostil) and 15(S)-15-methyl-PGE1 were inactive; however, misoprostol, enisoprost, and SC-46275 protected against colonic inflammation with ED50 values of 24, 12 and 1.3μg/kg, respectively, in rats and 11, 5, and 1μg/kg, respectively, in mice. These compounds may have utility in the medical management of human inflammatory bowel disease.


Acetic Acid Prostaglandin Inflammatory Bowel Disease Bowel Disease Medical Management 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    MacDermott, R. P., andW. F. Stenson. 1988. Alterations of the immune system in ulcerative colitis and Crohn's disease.Adv. Immunol. 42:285–328.Google Scholar
  2. 2.
    Sharon, P., andW. F. Stenson. 1984. Enhanced synthesis of leukotriene B4 by colonie mucosa in inflammatory bowel disease.Gastroenterology 86:453–460.Google Scholar
  3. 3.
    Stenson, W. F. 1988. Arachidonic acid metabolites in inflammatory bowel disease.Adv. Inflam. Res. 12:215–222.Google Scholar
  4. 4.
    Norris, A. A., 1989. Animal models of inflammatory bowel disease.In Pharmacological Methods in the Control of Inflammation. J. Y. Chang, A. J. Lewis, editors. Alan R. Liss, New York. 321–342.Google Scholar
  5. 5.
    Fretland, D. J., S. Levin, B. S. Tsai, S. W. Djuric, D. L. Widomski, J. M. Zemaitis, R. L. Shone, andR. F. Bauer. 1989. The effect of the leurotriene B4 receptor antagonist, SC-41930, on acetic acid induced colonic inflammation.Agents Actions 27:395–397.Google Scholar
  6. 6.
    Allgayer, H., K. Deschryver, andW. F. Stenson. 1989. Treatment with 16,16-dimethyl-prostaglandin E2 before and after induction of colitis with trinitrobenzenusulfonic acid in rats decreases inflammation.Gastroenterology 96:1290–1300.Google Scholar
  7. 7.
    Schumert, R., C. C. Nast, F. Cominelli, andR. D. Zipser. 1988. Effects of 16,16-dimethyl prostaglandin E2 and indomethacin on leukotriene B4 and inflammation in rabbit colitis.Prostaglandins 36:565–577.Google Scholar
  8. 8.
    Fedorak, R. N., L. R. Empey, C. MacArthur, andL. D. Jewell. 1990. Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats.Gastroenterology 98:615–625.Google Scholar
  9. 9.
    Collins, P. W. 1990. Misoprostol: Discovery, development and clinical applications.Med. Res. Rev. 10:149–172.Google Scholar
  10. 10.
    Collins, P. W., A. F. Gasiecki, W. E. Perkins, G. W. Gullikson, R. G. Bianchi, S. W. Kramer, J. S. Ng, E. E. Yonan, L. Swenton, P. H. Jones, andR. F. Bauer. 1990. Chemistry and structure-activity relationships of C-17 unsaturated 18-cycloalkyl and cycloalkenyl analogues of enisoprost.J. Med. Chem. 33:2784–2793.Google Scholar
  11. 11.
    Krawisz, J., P. Sharon, andW. F. Stenson. 1984. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity.Gastroenterology 87:1344–1350.Google Scholar
  12. 12.
    Keith, R., W. Smith, B. Tsai, S. Levin, andG. Butchko. 1985. Myeloperoxidase activity in experimentally induced colitis.Fed. Proc. 44:1545.Google Scholar
  13. 13.
    Boughton-Smith, N. K., J. L. Wallace, andB. J. R. Whittle. 1988. Relationships between arachidonic acid metabolism, myeloperoxidase activity and leukocyte infiltration in a rat model of inflammatory bowel disease.Agents Actions 25:115–123.Google Scholar
  14. 14.
    Rachmilewitz, D., P. Simon, L. Schwartz, D. Griswold, J. Fondacaro, andM. Wasserman. 1989. Inflammatory mediators of experimental colitis in rats.Gastroenterology 97:326–337.Google Scholar
  15. 15.
    Miller, M. J. S., X. -J, Zhang, X. Gu, andD. A. Clark. 1991. Acute intestinal injury induced by acetic acid and casein: Prevention by intraluminal misoprostol.Gastroenterology 101:22–30.Google Scholar
  16. 16.
    Goldin, E., andD. Rachmilewitz. 1983. Prostanoids cytoprotection for maintaining remission in ulcerative colitis: Failure of 15(R)-15-methyl prostaglandin E2.Dig. Dis. Sci. 28:807–811.Google Scholar
  17. 17.
    Collins, P. W. 1986. Development and therapeutic role of synthetic prostaglandins in peptic ulcer disease.J. Med. Chem. 29:437–443.Google Scholar
  18. 18.
    Torsher, K. J., L. K. Empey, andR. N. Fedorak. 1992. Misoprostol therapy following trinitrobenzene sulfonic acid-induced colitis accelerates healing.Prostaglandins Leukotrienes Essent. Fatty Acids 45:275–281.Google Scholar
  19. 19.
    Perkins, W. E., P. W. Collins, R. G. Bianchi, A. F. Gasiecki, R. F. Bauer, P. H. Jones, andT. S. Gaginella. 1991. Antisecretory, mucosal-protective and diarrhreagenic activity of a novel synthetic prostaglandin, SC-46275, in the rat.Drug Dev. Res. 23:349–358.Google Scholar

Copyright information

© Plenum Publishing Corporation 1992

Authors and Affiliations

  • D. J. Fretland
    • 1
  • D. L. Widomski
    • 1
  • C. P. Anglin
    • 1
  • R. E. Walsh
    • 1
  • S. Levin
    • 2
  • A. F. Gasiecki
    • 3
  • P. W. Collins
    • 3
  1. 1.Department of ImmunoInflammatory Diseases ResearchSearle Research and Development
  2. 2.Department of PathologySearle Research and Development
  3. 3.Department of ChemistrySearle Research and Development

Personalised recommendations